Ischaemia-modified albumin in pulmonary hypertension

Biomarkers

Volumn 15, Issue 3, 2010, Pages 238-242

  Sbarouni, Eftihia ^a   Georgiadou, Panagiota ^a   Manginas, Athanassios ^a   Panagiotakos, Demosthenes ^a   Karavolias, George K ^a   Voudris, Vassilis ^a  

^a ONASSIS CARDIAC SURGERY CENTER   (Greece)

Author keywords

Biomarkers; Ischaemia modified albumin; Pulmonary hypertension

Indexed keywords

ALBUMIN; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; CREATINE KINASE MB; DIGITALIS; DIURETIC AGENT; ISCHAEMIA MODIFIED ALBUMIN; PROSTACYCLIN; SILDENAFIL; TROPONIN I; UNCLASSIFIED DRUG; WARFARIN;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HEMODYNAMICS; HUMAN; ISCHEMIA; LUNG ARTERY PRESSURE; MALE; PROTEIN BLOOD LEVEL; PULMONARY HYPERTENSION;

ADULT; AGED; ALBUMINS; BIOLOGICAL MARKERS; BLOOD PRESSURE; CASE-CONTROL STUDIES; ECHOCARDIOGRAPHY; EXERCISE; FEMALE; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; SERUM ALBUMIN;

EID: 77951679949     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.3109/13547500903469994     Document Type: Article

References (36)

1. Abboud H, Labreuche J, Meseguer E, Lavallee PC, Simon O, Olivot JM, Mazighi M, Dehoux M, Benessiano J, Steg PG, Amarenco P. (2007). Ischemia modifed albumin in acute stroke. Cerebrovasc Dis 23:216-220
2. Apple FS, Quist HE, Otto AP, Mathews WE, Murakami MM. (2002). Release characteristics of cardiac biomarkers and ischemia-modifed albumin as measured by the albumin cobalt-binding test after marathon race. Clin Chem 48:1097-1100
3. Badesh DB, Champion HC, Sanchez MA, Hoeper MM, Loyd JE, Manes A, McGoon M, Naeije R, Olschewski H, Oudiz RJ, Torbicki A. (2009). Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol 54:S55-S66.
4. Christenson RH, Duh SH, Sanhai WR, Wu AH, Holtman V, Painter P, Branham E, Apple FS, Murakami M, Morris DL. (2001). Characteristics of an albumin binding test for assessment of acute coronary syndrome patients: a multicenter study. Clin Chem 47:464-470
5. Cichota LC, Moresco RN, Duarte MM, da Silva JE (2008). Evaluation of ischemia-modifed albumin in anemia associated to chronic kidney disease. J Clin Lab Anal 22:1-5.
6. Consuerga-Sanchez L, Boulas-Mosquera A, Sinha MK, Collinson PO, Gaze DC, Kaski JC. (2008). Ischemia-modifed albumin predicts short-term outcome and 1-year mortality in patients attending the emergency department for acute ischemic chest pain. Heart Vessels 23:174-180
7. Dominguez-Rodriguez A, Abreu-Gonzalez P, Jimenes-Sosa A, Samimi-Fard S, Idaira HB. (2009a). Does ischemia-modifed albumin add prognostic value to the Trombolysis in myocardial infarction risk score in patients with ST-segment elevation myocardial infarction treated with primary angioplasty? Biomarkers 14:43-48
8. Dominguez-Rodriguez A, Kaski JC, Abreu-Gonzalez P, Samimi-Fard S. (2009b). Role of ischemia modifed albumin to ST-segment resolution after mechanical reperfusion in patients with ST-segment elevation myocardial infarction. Atherosclerosis 203:576-580
9. Dominguez-Rodriguez A, Abreu-Gonzalez P, Garcia-Gonzales MJ, Samimi-Fard S, Reiter RJ, Kaski JC. (2008a). Association of ischemia-modifed albumin and melatonin in patients with ST-elevation myocardial infarction. Atherosclerosis 199:73-78
10. Dominguez-Rodriguez A, Abreu-Gonzalez P, Garcia-Gonzales MJ, Samimi-Fard S, Kaski JC. (2008b). Relation of ischemia-modifed albumin levels and left ventricular systolic function in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. Clin Chim Acta 388:196-199
11. Dusek J, St'ásek J, Tichy M, Bis J, Gregor J, Vojácek J, Masín V, Polanský P, Brtko M, Cernohorský D. (2006). Prognostic signif-cance of ischemia modifed albumin after percutaneous coronary intervention. Clin Chim Acta 367:77-80.
12. Falkensammer J, Stojakovic T, Huber K, Hammerer-Lercher A, Gruber I, Scharnagl H, Fraedrich G, Santner W, Schocke M, Greiner A. (2007). Serum levels of ischemia-modifed albumin in healthy volunteers after exercise induced calf-muscle ischemia. Clin Chem Lab Med 45:535-540
13. Fijalkowska A, Kurzyna M, Torbicki A, Szewczyk G, Florczyk M, Pruszczyk P, Szturmowicz M. (2006). Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension. Chest 129:1313-1321
14. Govender R, De Greef J, Delport R, Becker PJ, Vermaak WJ. (2008). Biological variation of ischemia-modifed albumin in healthy subjects. Cardiovasc J Afr 19:141-144
15. Hoeper MM, Oudiz RJ, Peacock A, Tapson VF, Haworth SG, Frost AE, Torbicki A. (2004). End points and clinical trial designs in pulmonary arterial hypertension: clinical and regulatory perspectives. J Am Coll Cardiol 43(Suppl. 12):48S-55S.
16. Kurz K, Voelker R, Zdunek D, Wergeland R, Hess G, Ivandic B, Katus H, Giannitsis E. (2007). Efect of stress-induced reversible ischemia on serum concentrations of ischemia-modifed albumin, natriuretic peptides and placental growth factor. Clin Res Cardiol 96:152-157
17. Lang RM, Bierig M, Devereux RB et al. (2005). Recommendations for Chamber Quantifcation: a report from the American Society of Echocardiography's guidelines and the Standards Committee and the Chamber Quantifcation Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 18:1440-1463
18. Nagaya N, Nishikimi T, Uematsu M, Satoh T, Kyotani S, Sakamaki F, Kakishita M, Fukushima K, Okano Y, Nakanishi N, Miyatake K, Kangawa K. (2000). Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 102:865-870
19. Peacock F, Morris DL, Anwaruddin S, Christenson RH, Collinson PO, Goodacre SW, Januzzi JL, Jesse RL, Kaski JC, Kontos MC, Lefevre G, Mutrie D, Sinha MK, Uettwiller-Geiger D, Pollack C V. (2006). Meta-analysis of ischemia-modifed albumin to rule out acute coronary syndromes in the emergency department. Am Heart J 152:253-262
20. Quiles J, Roy D, Gaze D, Garrido I P, Avanzas P, Sinha M, Kaski JC. (2003). Relation of Ischemia-Modifed Albumin (IMA) levels following elective angioplasty for stable angina pectoris to duration of balloon-induced myocardial ischemia. Am J Cardiol 92:322-324
21. Roy D, Quiles J, Sinha M, ldama G, Gaze D, Kaski JC. (2004a). Efect of direct-current cardioversion on ischemia-modifed albumin in patients with atrial fbrillation. Am J Cardiol 93:366-368
22. Roy D, Quiles J, Sinha M, Floros D, Gaze D, Collinson P, Baxter GF, Kaski JC. (2004b). Efect of radiofrequency catheter ablation on the biochemical marker ischemia-modifed albumin. Am J Cardiol 94:234-236
23. Sbarouni E, Georgiadou P, Koutelou M, Sklavainas I, Panagiotakos D, Voudris V (2009a). Ischaemia-modifed albumin in dilated cardiomyopathy. Ann Clin Biochem 46:241-243
24. Sbarouni E, Georgiadou P, Panagiotakos D, Alivizatos P, Voudris V. (2009b). Ischemia modifed albumin following coronary arterial bypass grafting. Biomarkers 14:38-42.
25. Sbarouni E, Georgiadou P, Panagiotakos D, Kyrzopoulos S, Tsiapras D, Voudris V, Kremastinos DT. (2008a). Ischemia modifed albumin in relation to pharmacologic stress testing in coronary artery disease. Clin Chim Acta 396:58-61.
26. Sbarouni E, Georgiadou P, Panagiotakos D, Livanis EG, Teodorakis GN, Kremastinos DT. (2008b). Te ischemia modifed albumin in relation to pacemaker and defbrillator implantation. Pacing Clin Electrophysiol 31:83-87
27. Sbarouni E, Georgiadou P, Panagiotakos D, Livanis EG, Teodorakis GN, Kremastinos D T. (2007). Ischaemia modifed albumin in radiofre-quency catheter ablation. Europace 9:127-129
28. Sbarouni E, Georgiadou P, Teodorakis GN, Kremastinos DT. (2006). Ischemia-modifed albumin in relation to exercise stress testing. J Am Coll Cardiol 48:2482-2484
29. Simonneau G, Robbins IM, Beghetti M, Channick RN, Delcroix M, Denton CP, Elliott CG, Gaine SP, Gladwin MT, Jing ZC, Krowka MJ, Langleben D, Nakanishi N, Souza R. (2009). Updated clinical classifcation of pulmonary hypertension. J Am Coll Cardiol 54:S43-S54.
30. Sinha MK, Gaze DC, Tippins JR, Collinson PO, Kaski JC. (2003). Ischemia modifed albumin is a sensitive marker of myocardial ischemia after percutaneous coronary intervention. Circulation 107:2403-2405
31. Torbicki A, Kurzyna M, Kuca P, Fijałkowska A, Sikora J, Florczyk M, Pruszczyk P, Burakowski J, Wawrzynska L. (2003). Detectable serum cardiac troponin T as a marker of poor prognosis among patients with chronic precapillary pulmonary hypertension. Circulation 108:844-848
32. Turedi S, Gunduz A, Mentese A, Karahan SC, Yilmaz SE, Eroglu O, Nuhoglu I, Turan I, Topbas M. (2007). Value of ischemia-modifed albumin in the diagnosis of pulmonary embolism. Am J Emerg Med 25:770-773
33. Turedi S, Gubduz A, Mentese A, Topbas M, Karahan SC, Yeniocak S, Turan I, Eroglu O, Ucar U, Karaca Y, Turkmen S, Russell RM. (2008). Te value of ischemia-modifed albumin compared with d-dimer in the diagnosis of pulmonary embolism. Resp Res 9:49.
34. Turedi S, Patan T, Gunduz A, Mentese A, Tekinbas C, Topbas M, Karahan SC, Yulug E, Turkmen S, Ucar U. (2009). Ischemia-modifed albumin in the diagnosis of pulmonary embolism: an experimental study. Am J Emerg Med 27:635-640
35. Van der Zee PM, Verberne HJ, Straalen JP, Sanders GT, Van Eck-Smit BL, de Winter RJ, Fischer JC. (2005). Ischemia-modifed albumin measurements in symptom-limited exercise myocardial perfusion scintigraphy refect serum albumin concentrations but not myocardial ischemia. Clin Chem 51:1744-1746
36. Warwick G, Tomas PS, Yates DH. (2008). Biomarkers in pulmonary hypertension. Eur Resp J 32:503-512